Ganaxolone: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Ganaxolone: clinical details
Prescribing considerations
- Initiation and supervision should be by a clinician experienced in epilepsy treatment.
- Use as adjunctive therapy for molecularly confirmed CDKL5 deficiency disorder within the licensed age context.
- Avoid abrupt withdrawal where possible because seizure frequency and status epilepticus may increase.
- Food markedly affects exposure; support consistent administration with or shortly after meals.
- Review concurrent CNS depressants, enzyme inducers, UGT inhibitors, alcohol use and any history of substance misuse.
- Exposure is substantially increased in severe hepatic impairment and requires an adjusted specialist plan.
Contraindications and cautions
- Hypersensitivity to ganaxolone or any formulation excipient.
- Cautions include clinically significant sedation, severe hepatic impairment, suicidal ideation or behaviour, substance-misuse history and concurrent CNS depressants.
Monitoring
- Seizure frequency and continuing clinical benefit
- Somnolence, sedation, lethargy, ataxia and functional impairment
- Mood, behaviour, suicidal ideation and self-harm behaviour
- Tolerability after treatment or interaction changes
- Clinical status in severe hepatic impairment
- Suspected adverse reactions under the UK additional-monitoring scheme
Clinical pharmacology
Ganaxolone is a methyl analogue of allopregnanolone and a positive allosteric modulator of GABA-A receptors. It undergoes extensive metabolism involving CYP3A4/3A5 and several CYP and UGT pathways. Food substantially increases systemic exposure, and severe hepatic impairment markedly increases exposure.
Formulation and product differences
- The oral suspension is white to off-white and supplied with reusable oral dosing syringes and bottle adaptors.
- The suspension contains benzoates, benzyl alcohol and parabens, which may cause excipient-specific adverse reactions in susceptible patients.
- Administration through an enteral feeding tube has not been established.
- Discard the opened bottle after 30 days.
Ganaxolone preparations and strengths
Oral suspension
Route: Oral
Strengths: 50 mg/mL
Ganaxolone interactions
Check prescribed, over-the-counter and herbal products with the specialist or pharmacist.
Carbamazepine, phenytoin, phenobarbital or primidone
These enzyme-inducing anti-seizure treatments can lower ganaxolone exposure and may reduce its effect.
Rifampicin
This strong enzyme inducer substantially lowers ganaxolone exposure, so combined use should generally be avoided.
St John’s wort
May lower ganaxolone exposure and should generally be avoided.
Valproate and other UGT inhibitors
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.